Details of the Drug Combination

General Information of Drug Combination (ID: DCSVVIU)

• Drug Combination Name: Veltuzumab + Epratuzumab Y-90
• Indication: Diffuse large B-cell lymphoma; Status: Phase 1 [1]
• Component Drugs:
  Veltuzumab (DM5BL4C): Monoclonal antibody
  Epratuzumab Y-90 (DMPGHCM): Monoclonal antibody

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Veltuzumab

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 2	[2]
Non-hodgkin lymphoma	2B33.5	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Systemic lupus erythematosus	4A40.0	Phase 2	[2]
Thrombocytopenia	3B64	Phase 1/2	[4]

Veltuzumab Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Modulator	[6]

Indication(s) of Epratuzumab Y-90

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[5]

References

• [1] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014 Nov;99(11):1738-45.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8268).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015033)
• [6] Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7.